KNSAライブシグナル | Getagraph.comで利益を最大化

売る 109197 min ago

@ $19.84

発行日: 14 2月 2024 @ 05:47

リターン: -7.76%

前回のシグナル: 2月 13 - 03:31

前回のシグナル: 買う

リターン: -4.34 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	116 266
平均出来高	375 501
時価総額	1.29B
EPS	$0 ( 2024-04-23 )
次の収益日	( $-0.140 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	140.77
ATR14	$0.0230 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Patel Sanj K	Buy	129 750	Share Option
2024-04-08	Patel Sanj K	Buy	9 992	Class A Common Share
2024-04-08	Patel Sanj K	Sell	4 075	Class A Common Share
2024-04-04	Patel Sanj K	Buy	24 950	Restricted Share Unit
2024-04-08	Patel Sanj K	Sell	9 992	Restricted Share Unit

INSIDER POWER
24.62
Last 100 transactions
Buy: 576 726 \| Sell: 364 070

ボリューム相関

長: -0.13 (neutral)

短: -0.72 (moderate negative)

Signal:(73.612) Neutral

Kiniksa Pharmaceuticals 相関

10 最も正の相関
CSSEP	0.955
EVLO	0.953
GOOD	0.952
SIRI	0.951
ORPH	0.95
ALXO	0.95
NAKD	0.95
AYTU	0.949
LSXMA	0.948
LSXMK	0.948

10 最も負の相関
CPAQ	-0.966
HERA	-0.966
TBSA	-0.965
AGGR	-0.965
LGAC	-0.965
ACQR	-0.964
APXI	-0.964
KAII	-0.964
FICV	-0.963
HERAU	-0.963

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kiniksa Pharmaceuticals 相関 - 通貨/商品

-0.07
( neutral )

0.05
( neutral )

0.00
( neutral )

0.37
( neutral )

0.73
( moderate )

-0.63
( weak negative )

Kiniksa Pharmaceuticals 財務諸表

Annual	2023
収益:	$270.26M
総利益:	$179.22M (66.31 %)
EPS:	$0.200

FY	2023
収益:	$270.26M
総利益:	$179.22M (66.31 %)
EPS:	$0.200

FY	2022
収益:	$220.18M
総利益:	$173.21M (78.67 %)
EPS:	$2.64

FY	2021
収益:	$38.54M
総利益:	$29.44M (76.39 %)
EPS:	$-2.30

Financial Reports:

No articles found.

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.